Answers are grounded in this paper and cite their sources.
We initiated a biomarker-informed preoperative study of infigratinib, a fibroblast growth factor receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations.
No takes yet. Share an insight, caveat, or question.
Matin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: